IMM002.69.47.4 (ATCC® CRL-13007)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte  /  Disease: Cancer

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension, with some loosely adherent cells
Biosafety Level 1
Disease Cancer
Strain BALB/c
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
Animals were immunized with a pool of plasmacytoma cells (U266, RPMI1860 and OPM) in the left footpad and with K562 chronic myelogenous leukemia cells in the right footpad. The immunization was repeated after 14 days. Lymph node cells were fused Sp2/0 mouse myeloma cells. The antibody is reactive with cell surface membranes of both human myeloma cells and ovarian cancer cells. MA69 detects a distinct band on myeloma membranes binding to a cell surface glycoprotein with an estimated molecular weight of between 78 and 120 kDa. The antibody also recognizes an antigen on ovarian cancer cells with a molecular weight of 76 kDa to 213 kDa. The antigen shares at least one epitope with the multiple myeloma surface antigen. MA69 is not reactive with cell surface membranes of human peripheral blood mononuclear cells, human B cells, neuroblastoma cells, human B cell myelogenic leukemia cells, breast cancer cells, prostate cancer cells, or cervical cancer cells.
Comments
Animals were immunized with a pool of plasmacytoma cells (U266, RPMI1860 and OPM) in the left footpad and with K562 chronic myelogenous leukemia cells in the right footpad. The immunization was repeated after 14 days. Lymph node cells were fused Sp2/0 mouse myeloma cells. The antibody is reactive with cell surface membranes of both human myeloma cells and ovarian cancer cells. MA69 detects a distinct band on myeloma membranes binding to a cell surface glycoprotein with an estimated molecular weight of between 78 and 120 kDa. The antibody also recognizes an antigen on ovarian cancer cells with a molecular weight of 76 kDa to 213 kDa. The antigen shares at least one epitope with the multiple myeloma surface antigen. MA69 is not reactive with cell surface membranes of human peripheral blood mononuclear cells, human B cells, neuroblastoma cells, human B cell myelogenic leukemia cells, breast cancer cells, prostate cancer cells, or cervical cancer cells.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 10(4) viable cells/ml. Adherent cells may be removed by shaking the flask.
Interval: Maintain cell density between 5 X 10(4) and 5 X 10(5) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype IgG1 kappa
Name of Depositor ImmunoTherapy, Inc.
References

Gelber G. Myeloma cell and ovarian cancer cell suface glycoproteins, antibodies thereto, and uses thereof. US Patent 6,376,654 dated Apr 23 2002

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Gelber G. Myeloma cell and ovarian cancer cell suface glycoproteins, antibodies thereto, and uses thereof. US Patent 6,376,654 dated Apr 23 2002